These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Specific effects of ecstasy and other illicit drugs on cognition in poly-substance users. Schilt T; de Win MM; Jager G; Koeter MW; Ramsey NF; Schmand B; van den Brink W Psychol Med; 2008 Sep; 38(9):1309-17. PubMed ID: 17988417 [TBL] [Abstract][Full Text] [Related]
4. Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol. Indlekofer F; Piechatzek M; Daamen M; Glasmacher C; Lieb R; Pfister H; Tucha O; Lange KW; Wittchen HU; Schütz CG J Psychopharmacol; 2009 Jul; 23(5):495-509. PubMed ID: 18635709 [TBL] [Abstract][Full Text] [Related]
5. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479 [TBL] [Abstract][Full Text] [Related]
6. Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. Schilt T; de Win MM; Koeter M; Jager G; Korf DJ; van den Brink W; Schmand B Arch Gen Psychiatry; 2007 Jun; 64(6):728-36. PubMed ID: 17548754 [TBL] [Abstract][Full Text] [Related]
7. Ecstasy (MDMA) exposure and neuropsychological functioning: a polydrug perspective. Medina KL; Shear PK; Corcoran K J Int Neuropsychol Soc; 2005 Oct; 11(6):753-65. PubMed ID: 16248911 [TBL] [Abstract][Full Text] [Related]
8. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users. Fox HC; McLean A; Turner JJ; Parrott AC; Rogers R; Sahakian BJ Psychopharmacology (Berl); 2002 Jul; 162(2):203-14. PubMed ID: 12110998 [TBL] [Abstract][Full Text] [Related]
9. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study. de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910 [TBL] [Abstract][Full Text] [Related]
10. Metamemory in recreational ecstasy polydrug users: what do self-reports of memory failures mean? Bedi G; Redman J J Psychopharmacol; 2008 Nov; 22(8):872-81. PubMed ID: 18208933 [TBL] [Abstract][Full Text] [Related]
11. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? Morgan MJ; McFie L; Fleetwood H; Robinson JA Psychopharmacology (Berl); 2002 Jan; 159(3):294-303. PubMed ID: 11862362 [TBL] [Abstract][Full Text] [Related]
14. Neural mechanisms of working memory in ecstasy (MDMA) users who continue or discontinue ecstasy and amphetamine use: evidence from an 18-month longitudinal functional magnetic resonance imaging study. Daumann J; Fischermann T; Heekeren K; Thron A; Gouzoulis-Mayfrank E Biol Psychiatry; 2004 Sep; 56(5):349-55. PubMed ID: 15336517 [TBL] [Abstract][Full Text] [Related]
15. The effects of stereotype threat on cognitive function in ecstasy users. Cole JC; Michailidou K; Jerome L; Sumnall HR J Psychopharmacol; 2006 Jul; 20(4):518-25. PubMed ID: 16174670 [TBL] [Abstract][Full Text] [Related]
16. Chronic ecstasy (MDMA) use is associated with deficits in task-switching but not inhibition or memory updating executive functions. Dafters RI Drug Alcohol Depend; 2006 Jun; 83(2):181-4. PubMed ID: 16316723 [TBL] [Abstract][Full Text] [Related]
17. Is moderate substance use associated with altered executive functioning in a population-based sample of young adults? Piechatzek M; Indlekofer F; Daamen M; Glasmacher C; Lieb R; Pfister H; Tucha O; Lange KW; Wittchen HU; Schütz CG Hum Psychopharmacol; 2009 Dec; 24(8):650-65. PubMed ID: 19946940 [TBL] [Abstract][Full Text] [Related]
18. The association between the negative effects attributed to ecstasy use and measures of cognition and mood among users. Fisk JE; Montgomery C; Murphy PN Exp Clin Psychopharmacol; 2009 Oct; 17(5):326-36. PubMed ID: 19803632 [TBL] [Abstract][Full Text] [Related]
19. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)]. Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451 [TBL] [Abstract][Full Text] [Related]
20. Self-reports of executive dysfunction in current ecstasy/polydrug Users. Hadjiefthyvoulou F; Fisk JE; Montgomery C; Bridges N Cogn Behav Neurol; 2012 Sep; 25(3):128-38. PubMed ID: 22960437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]